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Breast cancer is one of the most common types of cancer and the leading cause of cancer-
related death in women worldwide. Depressive symptoms, common during non-metastatic 
breast cancer, can be overlooked and therefore, undertreated. Researchers have previously 
evaluated the efficacy of Cognitive Behaviour Therapy (CBT) in treating depression in breast 
cancer patients. However, research investigating the short- and longer-term effectiveness of 
CBT-based interventions (CBT-BI) in a comprehensive manner is limited, with study quality 
seldom examined. To address this gap, this meta-analysis searched six electronic databases, 
identifying six randomised controlled trials (RCT) that examined the effectiveness of CBT-BI 
for depression in women with non-metastatic breast cancer (Nparticipants = 710). Standardised 
mean differences between intervention and control groups on self-report depression measures 
were calculated. Results highlighted that short-term CBT-BI (Hedge’s g = -1.215), 
particularly individual CBT-BI (Hedge’s g = -1.999), significantly reduced depression in 
comparison to control groups, while group CBT-BI demonstrated a medium but non-
significant effect (Hedge’s g = -.578). CBT-BI also decreased depression levels at three-
month follow-up, however, this effect was not maintained at six- and 12-month follow-up. 
Additionally, quality of included studies was explored in terms of risk of bias, study quality, 
intervention description, and researcher allegiance, and was found to be of moderate quality. 
A thorough investigation of CBT-BI, such as conducted in the current research, 
encourages evidence-based practice by allowing clinicians to more accurately gauge 
the efficacy of such interventions in treating depression amongst this population, thus, 
facilitating the development of optimal treatment protocols to improve clinical practices. 
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Chapter 1: Introduction 
1.1 Definition and Incidence of Breast cancer 
Cancer, a multifactorial disease instigated by somatic mutations in abnormal cells 
forming an invasive (or malignant) tumour, can occur in any part of the human body, 
including the breast (Australian Institute of Health and Welfare [AIHW] & Cancer Australia, 
2012). Upon cancer diagnosis, staging of cancer (0, I, II, III, or IV) determines the anatomic 
extent of the disease (Brierley, Gospodarowicz, & O’Sulivan, 2016). Stages 0-III are 
considered early-stage or non-metastatic, while Stage IV is termed advanced or metastatic.  
Metastatic cancer is an invasive tumour that spreads beyond the breast to other parts of the 
body (Edge, Byrd, Compton, Fritz, Greene, & Trotti, 2010). 
In 2015, approximately 2.4 million women globally were diagnosed with breast 
cancer, making it the most common cancer amongst women (DeSantis et al., 2016; 
Fitzmaurice et al., 2017) and being identified as the leading cause of cancer-related death 
among women (Fitzmaurice et al., 2017). In Australia, breast cancer affects one in eight 
women and one in 37 women will die from it before the age of 85 years (AIHW & Cancer 
Australia, 2012).  
1.2 Impact of Breast Cancer on Physical and Psychological Wellbeing 
Due to advances in medical technology, a greater number of women are surviving 
breast cancer (Ban & Godellas, 2014), although, significant adverse impacts on their physical 
and psychosocial wellbeing remain (Agarwala & Riba, 2010). The most common physical 
impacts experienced by women include chemotherapy-related side-effects such as nausea, 
loss of libido, and hot flushes (Agarwala & Riba, 2010; Fobair et al., 2006; Kim et al., 2018). 
Whilst these issues are physical in origin, they also often affect a woman’s psychological 
wellbeing. One key psychological consequence of breast cancer is depression, the focus of 
the current research. 




1.2.1 Depression in breast cancer. 
1.2.1.1 Classification and diagnosis of depression. 
Since the 1960s, depression, characterised by excessive rumination (Nestler et al., 
2002), has been diagnosed as “major depression” based on symptomology outlined in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM; American Psychiatric 
Association [APA], 2013). According to the DSM-V, individuals need to satisfy a number of 
criteria to receive a diagnosis of Major Depressive Disorder (MDD). First, from a series of 
possible symptoms, individuals must experience at least five symptoms nearly every day 
during the same two-week period, with at least one symptom being depressed mood or loss of 
interest / pleasure. These symptoms include decrease / increase in appetite or significant 
weight loss / weight gain; insomnia / hypersomnia; psychomotor agitation / retardation; 
fatigue / loss of energy; feelings of worthlessness / excessive or inappropriate guilt; and 
diminished ability to think or concentrate / indecisiveness. Individuals may also experience 
recurrent thoughts of death, suicidal ideation, or a suicide attempt (APA, 2013). 
MDD diagnoses among breast cancer populations may be difficult to make, as the 
symptoms observed may result from the physical aspects of cancer (Rodin et al., 2007). 
Furthermore, differences exist between being diagnosed with MDD, and presenting with 
depressive symptomology which commonly arises due to factors such as cancer-related 
therapy and side-effects, fear of recurrence, and life stresses (Bower, 2008; Jassim, Whitford, 
Hickey, & Carter, 2015). Consequently, one may not satisfy all criteria for a diagnosis of 
MDD but may still experience depressive symptoms, as Bower (2008) noted that 20% to 30% 
of women with non-metastatic breast cancer experienced increased depressive 
symptomology, although the prevalence of MDD amongst them was considerably lower. For 
the purpose of this research, the term depression is investigated broadly with the inclusion of 
depressive symptoms. 




1.2.1.2 Rates of depression in breast cancer. 
Breast cancer is highly associated with depressive symptoms and MDD with rates 
ranging from 20% to 58% and 11% to 13%, respectively (Abad, Bakhtiari, Kashani, & 
Habibi, 2016; Bower, 2008; Burgess et al., 2005; Fann et al., 2008; Jassim et al., 2015; Torta 
& Ieraci, 2013; Zabora, Brintzenhofeszoc, Curbow, Hooker, & Piantadosi, 2001). Depression 
has been commonly ascribed to the debilitating nature of breast cancer, fears surrounding 
diagnosis and treatment, and likelihood of poor outcomes (Sharpley & Christie, 2007), 
resulting in lower treatment compliance, reduced quality of life and higher rates of relapse 
following treatment (Fann et al., 2008; Li et al., 2016; Sharpley & Christie, 2007).  
Depression rates amongst women with non-metastatic breast cancer vary depending 
on time since diagnosis, with rates up to 30% in the initial six months (Akechi, Okuyama, 
Imoto, Yamawaki, & Uchitomi, 2001; Fallowfield, Hall, Maguire, & Baum, 1990; Hopwood, 
Howell, & Maguire, 1991), reducing to 25% and 15% in the second year and fifth year, 
respectively (Burgess et al., 2005). Additionally, evidence proposes that depression 
prevalence is also influenced by disease stage, with higher rates found in women with 
metastatic disease (23% to 45%; Hopwood et al., 1991; Hotopf, Chidgey, Addington-Hall, & 
Lan Ly, 2002; Kissane et al., 2004).  
1.3 Cognitive Behaviour Therapy for Depression in Breast Cancer  
The current research draws from Aaron Beck’s Cognitive Theory of Depression, 
developed in 1963 (Beck, 1963), in which he explained that those experiencing depression 
demonstrate automatic, repetitive cognitions pertaining to themes of loss and exhibiting 
negative views of the self, the world, and the future (cognitive triad). The level of such 
cognitions and dysfunctional beliefs are associated with depressive schemas being activated 
in response to certain stressors, and thus, directly related to depression severity (Beck, Rush, 
Shaw, & Emery, 1979; Haaga, Dyck, & Ernst, 1991; Kovacs & Beck, 1978). Based on 




Beck’s (1963) theory, CBT was formulated, one of the most widely used psychological 
interventions for depression and been proven to be effective in reducing depressive 
symptoms in a range of populations (Butler, Chapman, Forman, & Beck, 2006; Hollon, 
Stewart, & Strunk, 2006). CBT may include any form of psychotherapy delivered in an 
individual or group setting (Jassim et al., 2015). 
1.3.1 Processes involved in CBT/CBT-BI and impact of CBT-BI on depression in 
women with breast cancer. 
To treat depression, CBT uses a goal-orientated approach to target and modify 
dysfunctional cognitions and behaviours, and excessive rumination through cognitive 
restructuring and teaching specific coping skills (Cuijpers, Smit, Bohlmeijer, Hollon, & 
Andersson, 2010; Hopko et al., 2011; Hundt, Mignogna, Underhill, & Cully, 2013; Jassim et 
al., 2015). Patients use these skills to change specific (usually negative) cognitions and 
behaviours (Hundt et al., 2013).  
CBT consists of a variety of approaches which can be subdivided into third-wave 
therapies, such as mindfulness, cognitive behavioural stress management (CBSM), cognitive-
existential group therapy (CEGT), and acceptance and commitment therapy (Dahl, Wilson, & 
Nilsson, 2004; Jassim et al., 2015). Therefore, treatment can include various other 
components such as progressive cognitive therapy and muscle relaxation, meditation, and 
systematic desensitisation (Jassim et al., 2015). 
CBT-based interventions (CBT-BI) have shown to be effective in addressing 
depression in women with breast cancer (Brothers, Yang, Strunk, & Andersen, 2011; 
Carlson, Speca, Patel, & Goodey, 2003; Daniels, 2015; Jassim et al., 2015; Lengacher et al., 
2009; Tatrow & Montgomery, 2006). By promoting awareness through psychoeducation, and 
providing emotional support and cognitive restructuring skills, CBT-BI assists women to 




better cope with their disease by targeting the depression-induced cognitive dysfunctions (see 
Figure 1), which commonly occur in cancer (Fann et al., 2008; Sandgren & McCaul, 2007).  
 















Figure 1. Theoretical model of depression in women with breast cancer. Adapted from 
“Major depression a  fter breast cancer: a review of epidemiology and treatment,” by J.R. 
Fann, A.M. Thomas-Rich, W.J. Katon, D. Cowley, M. Pepping, B.A. McGregor, and J. 
Gralow, 2008, General Hospital Psychiatry, 30(2), pg. 120. Copyright 2008 by Elsevier Inc. 
 
1.4 Evidence-Based Practice 
Over the past few decades, there has been an increased call for evidence-based 
practice (EBP) with health care policies incorporating it as a central tenet (McHugh & 
Barlow, 2010). EBP is frequently used to treat physical components of breast cancer, but is 
also warranted for the associated psychological impacts, including depression (Drake et al., 
2001). Translating research findings into clinical practice is essential and is dependent on 
clinicians administering psychological interventions on the basis of published research 
findings (McHugh & Barlow, 2010). Despite this, evidence-based psychological practices 
across mental health remain under-developed, with research confirming the lack of successful 
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dissemination and implementation of research findings in clinical practice settings (Goisman, 
Warshaw, & Keller, 1999; Stewart & Chambless, 2007).  
This review recognises that clinicians must employ EBP to best assist women with 
breast cancer and depression. However, in order for clinicians to make insightful decisions 
about which interventions to implement in sound EBP, they must have accurate research 
evidence regarding intervention effectiveness based on gold standard RCTs and meta-
analyses (Dragioti, Dimoliatis, & Evangelou, 2015; Meline, 2006). 
1.5 Methodological Issues in the Breast Cancer, Depression and Psychological 
Intervention Literature  
CBT-BI have gained extensive recognition in reducing improving depressive 
symptoms among cancer patients through systematic reviews and meta-analyses (Barsevick, 
Sweeney, Haney, & Chung, 2002; Bower, 2008; Devine & Westlake, 1995; Meyer & Mark, 
1995), however many gaps in knowledge remain with regards to the effectiveness of such 
treatments. For example, little is known about whether treatment setting, mode of delivery, 
and length of intervention influence outcomes. Furthermore, the findings of these meta-
analyses are limited by methodological concerns, including small sample sizes, highly biased 
studies, and a paucity of RCTs, which limit the scope of interpretation.  
A review of the current literature revealed that some meta-analyses have only 
searched a small number of databases; Cobeanu & David (2018) searched only two 
databases, while  Haller and colleagues (2017) searched three. Additionally, Haller and 
colleagues' (2017) meta-analysis included women with both non-metastatic and metastatic 
breast cancer, which may be problematic due to differing rates of depression across disease 
stages. Also, depression was not the primary outcome of interest for Haller et al. (2017) and 
quality assessment of included studies was not undertaken. 




Two other meta-analyses in the area also raise methodological concerns; one 
examined the effectiveness of CBT in people with mixed cancers, including both breast 
cancer patients and survivors (Piet, Würtzen, & Zachariae, 2012), while another study 
(Cramer, Lauche, Paul, & Dobos, 2012) failed to report quality assessments. Additionally, 
two meta-analyses assessed only short-term effects of CBT-BI (Haller et al., 2017; Zhang, 
Xu, Wang, & Wang, 2016), despite recommendations that long-term benefits of CBT-BI 
ought to be further explored to enhance clinical practices (Butler et al., 2006; Newell, 
Sanson-Fisher, & Savolainen, 2002; Qiu et al., 2013). 
In light of these findings, the literature and clinical field would benefit from meta-
analyses that specifically: (1) examine interventions designed to target depression as the 
primary outcome in women with non-metastatic breast cancer; (2) use well-validated 
measures of depression; (3) include RCTs only; (4) conduct an extensive database search 
over a longer period of time; (5) assess both short- and longer-term effects of CBT-BI; and 
(6) conduct comprehensive quality assessments.  
1.6 Research Aims of the Current Study 
The aforementioned methodological concerns of previous studies impact researchers’ 
and clinicians’ abilities to make judgments about the reliability and validity of the 
effectiveness of CBT-BI for depression in women with breast cancer. In order to address 
these concerns, this comprehensive systematic review and meta-analysis examines the 
efficacy of CBT-BI for treating depression in women with non-metastatic breast cancer 
Specifically, the current research aims to: 
1. Examine the short-term effectiveness of CBT-BI for treating depression among 
women with non-metastatic breast cancer; 
2. Examine the longer-term effectiveness of CBT-BI for treating depression among 
women with non-metastatic breast cancer; 




3. Evaluate the quality of studies included in the meta-analysis in terms of risk of bias, 




























Chapter 2: Method 
2.1 Literature Search 
A comprehensive search of six databases (CINHL, Embase, PsycINFO, PubMed, 
Scopus, and Web of Science) was conducted for the period between database commencement 
and June 2018 to source suitable studies that have examined CBT-BI for depression in 
women with non-metastatic breast cancer. Search strategies were saved so that regular email 
updates could be delivered for any new results that matched the search criteria. Search terms 
were tailored to individual databases and comprised a range of extensive keywords, as listed 
in Table 1 (refer to Appendix A for detailed search strategies). To ensure accuracy, an expert 
research librarian assisted with the development of search terms. Additionally, the reference 
lists of included studies and past meta-analyses in the field were examined to detect any 




Search Terms and Boolean (Logical) Operators used in the Database Searches 
 
  
Breast Cancer Depression Psychological 
Intervention (CBT) 
Study Type 
Breast neoplasm* Depression Cognitive therapy Random allocation 
Breast carcinoma* Depressive disorder Cognitive behavioural 
therapy 
Randomized 
Breast tumour* Depressive Cognitive behav* Randomized 




Breast malignan* Distress* CBSM Randomised control 
trial* 
Cancer of the breast* Major depressive 
disorder* 
CBT RCT* 










Depressive episode* Cognitive therap* Randomised clinical 
trial* 
Non-metastatic breast  Cognitive behav* Randomized clinical 
OR 
AND 




Note. Search terms includes stated terms and derivatives *(e.g., behaviour and behavioural). Both plural and 
singular terms searched. 
 
 
2.2 Eligibility Criteria 
To enhance scientific rigour in meta-analyses of clinical or healthcare questions, it is 
recommended that the research question be formed in terms of Population (P), Intervention 
(I), Comparison (C) and Outcomes (O), using the PICO framework (Burns & Chung, 2010; 
Gillam & Siriwardena, 2014; Moher et al., 2009; Morton, Berg, Levit, & Eden, 2011). Thus, 
study inclusion in the current research was guided by following this framework: Population – 
breast cancer; Intervention – CBT-BI; Comparison – control group (waitlist control/standard 
care); and Outcomes - depression. 
This meta-analysis included studies if they satisfied the following criteria: (1) 
evaluated change in depression as a primary outcome of participation in interventions 
undertaken in a RCT; in (2) women with non-metastatic breast cancer over the age of 18 
years diagnosed with depression; who (3) participated in a CBT-BI or control group; where 
(4) depression was assessed using a validated self-report instrument (e.g., HADS, BDI-II, 
CES-D); and (5) baseline and post-intervention measures of depression were reported. In 
addition, studies had to (6) provide parametric data to enable the calculation of an effect size 
(i.e., means, SDs, exact p values), and (7) be published in the English language.  
Studies examining multiple stages (Stages 0-IV) of breast cancer, where data for 
individual stages could not be separately extracted, were excluded. Secondly, studies which 
only included women with metastatic breast cancer were excluded because their survival 
rates decline dramatically, and their psychosocial concerns differ (e.g., greater importance of 
neoplasm* therap* trial* 
Non-metastatic breast 
carcinoma* 
   
Lobular carcinoma*    
Ductal carcinoma*    
Breast cancer*    




symptomatic relief) compared with women diagnosed at earlier stages (Nápoles et al., 2015; 
Reich, Lesur, & Perdrizet-Chevallier, 2008). Lastly, breast cancer survivors, defined as those 
not undergoing active treatment(s) to manage their cancer, were also excluded. 
The initial literature search returned 340 articles across the databases (see Figure 2). 
Removal of duplicates narrowed the pool of studies to 220. The title and abstracts of these 
articles were subsequently screened against the selection criteria, leaving 59 articles. The 
full-text versions of these remaining articles were retrieved and re-screened against the 
inclusion/exclusion criteria, resulting in five eligible studies. An additional article was 
sourced from other articles’ reference lists and upon assessment, was also included in the 
review. Three authors (Abad et al., 2016; Antoni et al., 2001; Simpson, Carlson, & Trew, 
2001) were contacted by the author (SC) to obtain additional information, as the data 
provided was insufficient to draw conclusions about inclusion/exclusion. Of these, one author 
(Antoni et al., 2001) provided further data, and as a result, their study was included in the 
analysis, taking the number of eligible studies to six. Several other relevant papers were 
identified but were study protocols only, thus were excluded. Where possible, the first author 
(SC) contacted lead authors to check whether any published data was available. Of the three 
authors contacted, one (Low et al., 2016) replied indicating that their study was unpublished 
and under review. All these follow-ups resulted in a final sample of six studies.  
Reliability of this article selection process was checked by a second reviewer (thesis 
supervisor, MO), who screened titles and abstracts of 10% of potentially eligible studies, 
randomly chosen by the primary reviewer (SC). Inter-rater reliability was high, with 
agreement among raters achieved on 97% of occasions (K = .94, p < .05) (McHugh, 2012). 
Any discrepancies were discussed and resolved by consensus. 





Figure 2. PRISMA flowchart of study selection process. Adapted from “Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement,” by D. Moher, A. 








2.3 Data Collection and Preparation 
In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Moher et al., 2009), and evidence-based recommendations 
for the reporting of systematic and meta-analytic reviews (Moher, Liberati, Tetzlaff, & 
Altman, 2010), key information for each study was summarised using a data extraction sheet 
(see Appendix B). This included information relating to: (1) sample characteristics and 
demographics (e.g., sample size, recruitment source, age range and mean, gender, cancer 
stage); (2) study characteristics (e.g., study design, standardised outcome measures); (3) 
effect size estimates (e.g., means, standard deviations, p values); and (4) treatment 
characteristics (e.g., therapy format and modality, frequency, and duration).  
2.4 Statistical Analysis 
Both short-term (i.e., change in depression score from baseline to first assessment 
reported post-intervention) and longer-term treatment effects (i.e., change in depression score 
from baseline to three, six and 12-month follow-up) were calculated using Hedges g effect 
size (Borenstein, Hedges, Higgins, & Rothstein, 2009). Longer-term was defined as pre-
intervention to follow-up assessments, rather than post-intervention to follow-up 
assessments because three studies (Arving et al., 2007; Kissane et al., 2003; Marchioro et al., 
1996) did not conduct an immediate post-intervention assessment of depression. One study 
(Desautels, Savard, Ivers, Savard, & Caplette-Gingras, 2018) was excluded from longer-term 
analysis as participants as participants initially in the control condition were later reassigned 
to receive CBT-BI and thus, if included, this study may have potentially contaminated any 
possible effect. 
Effect size data was entered into Comprehensive Meta-Analysis (CMA) Software 
Version 3 (Borenstein, Hedges, Higgins, & Rothstein, 2014). As recommended by Cumming 
(2012), a random-effects model of meta-analysis was utilised. This model assumes that 




variation between observed effect sizes is due to subject-level sampling error and differences 
within individual study designs (Lipsey & Wilson, 2001). 
Effect sizes were computed using means and standard deviations (SD). The 
depression outcome measure scores were entered as continuous data, with the effect size 
calculated being the standardised mean difference (SMD) between CBT-BI and control 
groups, with 95% confidence intervals (CI) indicating the difference in means between 
groups, divided by the pooled SD. If studies examined multiple intervention groups (Arving 
et al., 2007; Desautels et al., 2018), only the relevant intervention data on CBT-BI and 
depression was used. One study (Desautels et al., 2018) used multiple self-report measures 
and a clinician measure of depression. For this, only the self-report measure was used, with 
an average effect size calculated and used in subsequent pooled analyses to ensure 
consistencies between effect size analyses. Rosenthal’s (1993) recommendation of using a 
conservative estimate (r = .7) in cases, where correlations between the pre- and post-
treatment measures were unavailable in within-group designs, was employed. To calculate 
the mean effect size for a group of studies, individual effect sizes were pooled using a 
random-effects model rather than a fixed-effect model as the included studies were not 
identical in design. 
While Cohen’s d is one SMD estimate that is often used, it has been noted to have a 
positive bias, tending to overestimate the absolute value of effect size in small samples 
(Borenstein et al., 2009). This bias can be removed by instead using Hedge’s g (Borenstein et 
al., 2009). In this meta-analysis, the small number of included studies and discrepancies in 
samples sizes between these (sample size of smallest group = 11 and sample size of largest 
group = 154), made Hedges g the optimal effect size measure to use as it is useful for great 
diversity in samples (Borenstein et al., 2009; Ellis, 2010; Higgins & Green, 2011). The 
direction of the effect size estimate was standardised for ease of data interpretation, such that 




a negative Hedge’s g indicated improvement in depression symptoms amongst individuals 
who received CBT-BI compared to the control group. Effect sizes were interpreted using 
Cohen’s guidelines (0.2 = small, 0.5 = medium, and 0.8 = large effect) (Cohen, 1988). 
To ascertain the accuracy of individual and weighted effect sizes, exact p values and 
95% CIs were calculated. CIs reflect the range of values within which the true mean value 
lies. At the 95% level, there is only a 5% chance that the actual effect size will lie beyond 
the range of values specified by the CI (Stratford, 2010). Effect sizes were considered to be 
statistically significant when the CI did not include the value of zero.   
In addition, where possible, Orwin’s fail-safe Ns (Nfs) (Orwin, 1983) were calculated 
for effect size subsets to address possible publication bias which is a potential threat to the 
validity of this meta-analysis (Rosenthal & DiMatteo, 2001). Meta-analytic techniques may 
overestimate treatment effects as they can be subject to the “file drawer problem” – or a bias 
towards studies that report significant results (Orwin, 1983). This problem arises when the 
results of published and unpublished studies are systematically different, and reviews like 
the current one, rely on data from published studies only (Orwin, 1983). 
The Nfs reflects the number of unpublished or unidentified studies reporting no effect 
(i.e., no relationship) that would need to exist to produce a small effect size, defined in this 
review as an effect size of 0.20, as suggested by Orwin (1983). 
We calculated Nfs using Orwin (1983) fail-safe N formula (Eq. (11)): 
𝑁𝑓𝑠 =  
𝑁 (𝑑 − 𝑑𝑐)
𝑑𝑐
 
where N = the number of studies in the meta-analysis, d = the average effect size for the 
studies synthesized, and 𝑑𝑐 = the criterion value selected that d would equal when some 
knowable number of hypothetical studies (𝑁𝑓𝑠) were added to the meta-analysis. The value 
for 𝑑𝑐 was set at 0.2 (small effect). Generally, the higher the Nfs value the more confidence 
can be held in the result as it is more unlikely that there are unpublished studies that would 




contradict the findings (Ellis, 2010). This meta-analysis employed a conservative approach 
whereby, findings were considered robust when the Nfs value exceeded the number of 
studies contributing to an effect size estimate (i.e., Nfs > Nstudies). This differs from other Nfs 
formula, which rely on the total number of studies undergoing a meta-analysis (Zakzanis, 
2001).  
Finally, heterogeneity among studies in each group was systematically assessed. 
Heterogeneity tests the variation in study outcomes between studies (Borenstein et al., 
2009). This study used the I2 statistic and the chi-squared statistic (Cochrane’s Q; 
Borenstein et al., 2009; Haidich, 2010) to both evaluate the degree of consistency in pooled 
effect size estimates (Higgins & Green, 2011), and to test if there was a significant 
difference in the effect sizes between individual and group CBT-BI compared to control 
groups, respectively. The value of I2 denotes the percentage of observed between-studies 
variance that can be credited to real differences in effect sizes (heterogeneity) instead of 
chance (Higgins & Thompson, 2002; Higgins, Thompson, Deeks, & Altman, 2003). I2 
values of 2% are considered low; 50% considered moderate; and greater than 50% (i.e., 
75%) indicate considerable heterogeneity across individual effect size estimates (Brewin, 
Andrews, & Valentine, 2000; Higgins et al., 2003). Because I2 measures the proportion of 
heterogeneity to the total observed dispersion, it is not influenced by low statistical power 
and is not contingent on the number of studies included in the meta-analysis (Littell, 
Corcoran, & Pillai, 2008).  
In combination, these statistics were used to assess the effectiveness of CBT-BI in 
reducing depression among women with non-metastatic breast cancer. Specifically, CBT-BI 
was deemed to have an important effect on depression in women with breast cancer if it was: 
(1) associated with a medium (Hedge’s g ≥ .50) to large (Hedge’s g ≥ .80); (2) that was 
statistically significant (i.e., 95% CIs ≠ 0; p < .05); and (3) had a Nfs greater than the number 




of studies which contributed to the pooled effect size. The interpretation of these results was 
considered in the context of study heterogeneity.   
2.5 Quality Assessments 
Four forms of quality assessment, risk of bias, study quality, intervention description, 
and RA, were undertaken. 
2.5.1 Risk of bias assessment. 
Risk of bias assessment to evaluate methodological quality of included studies was 
conducted (see Appendix C) following Cochrane guidelines (Higgins et al., 2011). Studies 
were rated on critical aspects pertinent to clinical research (Pannucci & Wilkins, 2010), 
namely: internal validity (i.e.,  extent to which a study minimises systematic error by 
reducing biases in measurement and data collection), and external validity (i.e., extent to 
which the study findings can be generalised to the broader breast cancer and depression 
population).   
2.5.2 Quality assessment of included studies. 
Quality of included research studies was evaluated using the Quality Index (QI) 
developed by Downs & Black (1998). This 27-item scale examines three key areas that 
routinely contribute to methodological bias in health intervention research: external validity, 
internal validity, and study power. Each item is critically appraised and scored as either 1 or 
0, with additional points awarded if the study details potential confounders in the selection of 
study participants in addition to meeting the criteria for study power (i.e., statistically 
significant group difference of p < .05, with power at 80% for this review; Cohen, 1992). 
Item scores are summed to obtain an overall score between 0 and 32 which can be 
categorised as follows: excellent (26-32); good (20-25); fair (15-19); and poor (≤14) (Hooper, 
Jutai, Strong, & Russell-Minda, 2008). 
The QI has demonstrated good psychometric properties, including test-retest 




reliability (r = 0.88) and inter-rater reliability (r = 0.75; Downs & Black, 1998). Quality 
ratings were independently conducted by the author (SC) and second reviewer (MO). The 
results were compared and discrepancies were resolved by consensus. Correlations between 
total QI ratings revealed sound agreement between the two evaluators (Kendall’s Tau = 
0.600, p = .091) (Stemler, 2004). Kendall’s Tau is more robust than Spearman’s rho, and is a 
proxy for Pearson’s product-moment correlation in research where sample sizes are small, 
making it the preferable estimator from both perspectives (Croux & Dehon, 2010; Field, 
2009; Walker, 2016). Given the small number of studies and that Kendall’s Tau is based on 
the sample, and thus, highly affected by the sample size, it is predicted that the current results 
were non-significant for these reasons.  
2.5.3 Quality assessment of CBT-BI descriptions in included studies. 
An assessment of intervention descriptions was also undertaken because without 
complete published descriptions of interventions, researchers cannot replicate or add to 
research findings and clinicians cannot reliably implement effective interventions (Hoffmann 
et al., 2014). The Template for Intervention Description and Replication (TIDieR), was 
developed in response to the very poor quality of intervention descriptions in the literature 
(Hoffmann et al., 2014). Hence, this meta-analysis used TIDieR to evaluate the quality of 
intervention descriptions used in included studies. This 12-item checklist allows examination 
of the following areas that make it easier to understand and replicate effective interventions, 
especially in trials: brief name, why (rationale), what (materials), what (procedure), who 
provided, how, where, when and how much, tailoring, modifications, how well (planned), 
and how well (actual). 
2.5.4 Researcher allegiance (RA). 
The RA effect is very important in studies evaluating psychotherapeutic intervention 
effectiveness because researchers may portray allegiances which influence their actions or 




reporting of their results (Dragioti et al., 2015). Given that psychotherapeutic research is 
prone to RA as an influential factor, it has been recently suggested that RA should be 
routinely examined in meta-analyses (Dragioti et al., 2015). To address this issue, a RA 
checklist (Wampold et al., 2011) was used, whereby, a study was defined as showing RA 
when the author(s) had: (1) developed the intervention; (2) developed both the therapy and 
trained the therapists; (3) developed both the intervention and supervised the therapists; (4) 
supervised and/or trained the therapists alone; or (5) advocated the therapy. Studies are coded 
using a 6 category system (0 = No apparent advocacy of one treatment over another - 5 = 
Authors created intervention and supervised/trained therapist), with higher scores indicating 


























Chapter 3: Results 
3.1 Study Characteristics 
Six RCTs were included in this meta-analysis (see Table 2), published in peer-
reviewed journals between 1996 and 2018. Data originated from diverse areas around the 
world, with single studies from The United States of America, Australia, Canada, Sweden, 
Iran, and The United Kingdom. Sample sizes ranged from a small quasi-experimental study 
(Mohabbat-Bahar, Maleki-Rizi, Akbari, & Moradi-Joo, 2015) of 30 participants, to two 
RCTs (Desautels et al., 2018; Marchioro et al., 1996) of 62 and 36 participants, respectively. 
Two multi-center studies (Antoni et al., 2001; Kissane et al., 2003) contributed 403 
participants, with one study from Sweden (Arving et al., 2007) contributing an additional 179 
participants.  
A total of four depression measures were utilised across the six studies. The majority 
of studies relied on self-report measures (Nstudies = 6), with one study (Desautels et al., 2018) 
also including clinician rating of depression. The Beck Depression Inventory (BDI, BDI-II; 
(Beck, Steer, & Brown, 1996) and the Hospital Anxiety and Depression Scale (HADS; 
(Zigmond & Snaith, 1983) were the most commonly used measures. One study (Antoni et al., 
2001)  utilised the Center for Epidemiologic Studies Depression Scale (CES-D; Radloff, 
1977), while another (Desautels et al., 2018) used a clinician-assessed depression measure, 
the Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) in addition to the HADS and 
the BDI-II. Given that only one study used a clinician measure, the clinician data was not 
used in the analyses to prevent any potential confounding effects (Mohr, Boudewyn, 
Goodkin, Bostrom, & Epstein, 2001). The majority of studies (Nstudies = 4) relied on a single 
source for participant recruitment (e.g., single oncology unit), with participants approached 
directly by researchers or hospital staff for two studies (Arving et al., 2007; Mohabbat-Bahar 
et al., 2015) which can help maximise the representativeness of a sample. Two studies 




(Antoni et al., 2001; Desautels et al., 2018) used the broad recruitment strategy of 
Oncologists or Physicians sending a letter of invitation to potential participants.





Descriptive Characteristics of Included Studies (Nstudies = 6) 
Note. Measure Abbreviations: ABS, Affect Balance Scale; BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory-II; CES-D, Centre for Epidemiologic Studies 
Depression Scale; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; POMS, Profile of Mood States. 
*Study had two intervention groups, with one intervention group not included in the analysis (Bright light therapy; n = 26), as it was not relevant to this study.
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3.2 Participant Characteristics 
The total pooled sample included 710 individuals with non-metastatic breast cancer 
(see Table 3). All participants were female and the mean age of individuals was 
approximately 51.2 years, with one study (Marchioro et al., 1996) reporting a range of 35-65 
years. The majority of women had been diagnosed with Stage II breast cancer; Stage 0 was 
the least common diagnosis, although this data was inconsistently reported. All studies 
reported marital status with most participants being partnered or married (74.9%). Only one 
study (Antoni et al., 2001) reported the participant ethnicity, with the majority being Non-
Hispanic White (10.4%). Half of the studies (Desautels et al., 2018; Kissane et al., 2003; 
Marchioro et al., 1996) reported level of education; among those with reported data, the 
majority (nparticipants = 241) described their highest educational achievement as high-school or 
lower, with another 160 participants reporting tertiary/university education. Finally, two 
thirds of the total studies (Antoni et al., 2001; Desautels et al., 2018; Kissane et al., 2003; 
Marchioro et al., 1996) reported employment status, with 26.2% employed and 30% 
unemployed out of the total sample reporting this data (nparticipants = 501). 
Critical sample characteristics (e.g., age, gender) were provided by more than 80% of 
the studies; one study (Marchioro et al., 1996) did not provide specific data. Missing data was 
at least partially explained by all studies (e.g., by providing Nincomplete data, with reasons), 
thereby diminishing the risk of attrition bias.  
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Table 3  
Sociodemographic Characteristics and Medical History for Individuals With Breast Cancer 
for Included Studies (Nstudies = 6)  
 Note. Nstudies = number of studies providing data; Nparticipants = number of participants in which the data was 
provided.  
a Number varies within columns because not all studies reported this information. b Percentage (%) of 




Variable  Nstudiesa  Nparticipantsa 
(%) b 
M (SD)  Range  
Sample size  6 710 (100) 118.3 (105.7) 30-303 
Age at study  
recruitment (years)  
5 674 (94.9) 51.2 (6.03) 23-87 
Gender  









     Female  6 710 (100)   
Marital status  









     
Single/widowed/divorced  
6 176 (24.8)   
Stage of Breast Cancer 









    Stage 1  2 97 (13.7)   
    Stage 2  2 295 (41.6)   
    Stage 3 2 0 (0)   
Ethnicity 









     Hispanic 1 16 (2.3)   
    African  1 6 (0.9)   
    Other 1 4 (0.6)   
Education 3    
   <High-school 3 241 (3.9)   
   
College/University/Tertiary 
3 160 (22.5)   
Employment 4    
   Employed 4 186 (26.2)   
   Not Employed 4 213 (30)   
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3.3 Effect Size Estimates 
Five sub-analyses of CBT-BI were conducted in this meta-analysis. Of these, only 
three were considered clinically significant in accordance with the criteria adopted for this 
review (i.e., Hedge’s g ≥ .50; Nfs >N; CIs ≠ 0) for both short- and longer-term effects. This 
included sub-analyses of: pre-post treatment; individual versus group therapy; pre-treatment 
to three-, six-, 12-month follow-up. Effect size estimates varied considerably in their 
magnitude, as discussed below.  
3.3.1 Short-term findings. 
3.3.1.1 Overall short-term findings – pre-treatment to post-treatment. 
All six studies investigated the short-term effect of CBT-BI on depression. Effect size 
estimates (see Figure 3) suggested that overall, CBT-BI is highly effective in reducing 
depression in the short-term, in comparison to controls (Nstudies = 6, Hedge’s g = -1.215, 95% 
CIs [-1.931, -.295]; Nfs > Nstudies; p = .002). However, substantial heterogeneity was noted (I
2 
= 96%). The Nfs of 30 suggests this finding is somewhat robust, indicating that a substantial 
number of unpublished studies with non-significant results would need to exist to call this 
finding into question. 





Figure 3. Depression by CBT-BI for all studies from pre-treatment to first measurement post-treatment (short-term effect). A negative effect indicates 
that individuals in the intervention group experienced reduced depression scores as compared with the control group. CI = confidence interval. 
bAveraged scores of self-report depression measures used in the analysis. CI = confidence interval; bAveraged scores of self-report depression measures 































Antoni (2001) CES-D 1 100 -.179 .199 -.570         .211 .368 
Arving (2007) HADS 1 179 -.364 .130 -.619        -.109 .005 
Desautels (2018)b BDI 
HADS 
1 62 -5.681 .538 -6.735      -4.627 .000 
Kissane (2003) HADS 1 303 -.136 .115 -.361         .089 .237 
Marchioro (1996) BDI 1 36 -.439 .330 -1.086       .207 .183 
Mohabbat-Bahar 
(2015) 
BDI 1 30 -1.497 .404 -2.289      -.704 .000 
Overall (all studies) 6 710 -1.215 .398 -1.931      -.295 .002 
Hedge’s g and 95% CI 








Figure 4. Depression by CBT-BI comparing individual to group CBT-BI for all studies from pre-treatment to post-treatment. A negative effect indicates 
that individuals in the intervention group experienced reduced depression scores as compared with the control group. CI = confidence interval. a Averaged 
scores of depression measure for two interventions (INS and IPS) and a control, used in the analysis; b Averaged scores of self-report depression measures 
used in the analysis. 
 
 





























Antoni (2001) Group CES-D 1 100 -.179 .199 -.570         .211 .368 
Kissane (2003) Group HADS 1 303 -.136 .115 -.361         .089 .237 
Mohabbat-Bahar 
(2015) 
Group BDI 1 30 -1.497 .404 -2.289      -.704 .000 
Overall Group   3 433 -.578 .709 -1.968       .812 .415 
Arving (2007)a Individual HADS 1 179 -.364 .130 -.619        -.109 .005 
Desautels (2018)b Individual BDI 
HADS 
1 62 -5.681 .538 -6.735      -4.627 .000 
Marchioro (1996) Individual BDI 1 36 -.439 .330 -1.086       .207 .183 
Overall Individual   3 277 -1.999 .723 -3.417      -.518 .006 
Overall (all studies) 6 710 -1.274 .506 -2.267       -.282 .012 
Hedge’s g and 95% CI 
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3.3.1.2 Individual versus group CBT-BI. 
All studies were divided into sub-groups of either individual or group CBT-BI, and 
examined (see Figure 4). Findings demonstrate that CBT-BI delivered in an individual format 
showed a significant positive effect on depression compared to controls (nstudies = 6, Hedge’s 
g = -1.999, 95% CIs [-3.417, -.518]; Nfs  > Nstudies; p = .006). In contrast, group CBT-BI 
exhibited a medium, but non-significant effect on depression as compared to controls (Nstudies 
= 6, Hedge’s g = -.578, 95% CIs [-1.968, .812]; Nfs  > Nstudies; p = .415). Despite differences in 
effect size significance between the two formats, there was no evidence that CBT-BI 
delivered individually conferred more statistically significant benefits compared to that 
delivered in group format (Q = 1.176, df = 1, p = .278). However, substantial heterogeneity 
was noted (I2 = 96%). The 𝑁𝑓𝑠 was found to be 16 and 5 for individual and group CBT-BI, 
respectively, suggesting that this finding for individual CBT-BI is robust, while the results for 
group CBT-BI may be less robust. 
3.3.2 Longer-term findings. 
3.3.2.1 Pre-treatment to three-month follow-up. 
Two studies examined the longer-term effect of CBT-BI on depression at three-month 
follow-up (see Figure 5). The overall effect size estimate was medium and highly significant, 
suggesting that women who had undertaken CBT-BI had less depression compared to 
controls at three-month follow-up (nstudies = 2, Hedge’s g = -.490, 95% CIs [-.730, -.250]; Nfs 
< Nstudies; p < .001). However, 𝑁𝑓𝑠 was less than the number of studies included in the 
analysis, suggesting that this finding may not be robust and may be influenced by publication 
bias. Out of the two studies, Arving et al. (2007) was assigned the bulk of the weighting 
(86.06%). Statistical homogeneity (I2 = 0.00) was found, which could be credited to 
similarities in intervention procedures, including patients being assessed one-, three-, six-
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months post-intervention (nstudies = 2) in the individual studies (Arving et al., 2007; Marchioro 
et al., 1996). 
3.3.2.2 Pre-treatment to six-month follow-up. 
The overall effect size from the four studies which examined the effect of CBT-BI 
from pre-treatment to six-month follow-up was small in strength and, despite being close to 
obtaining statistical significance, was non-significant (see Figure 6). Thus, depression levels 
at six-month follow-up did not differ between the CBT-BI and control groups (nstudies = 4, 
Hedge’s g = -.193, 95% [-.391, .004]; Nfs < Nstudies; p = .055). Given the small Nfs statistic, 
this finding must be interpreted with caution as the results may be influenced by publication 
bias. 






Figure 5. Depression by CBT-BI for selected studies from pre-treatment to three-month follow-up (longer-term effect). A negative effect indicates 
that individuals in the intervention group experienced reduced depression scores as compared with the control group. CI = confidence interval; a 















Figure 6. Depression by CBT-BI for selected studies from pre-treatment to six-month follow-up 
(longer-term effect). A negative effect indicates that individuals in the intervention group experienced reduced depression scores as compared with the 































Arving (2007)a HADS 1 179 -.520 .132 -.779        -.261 .000 
Marchioro (1996) BDI 1 36 -.306 .328 -.949         .336 .350 
Overall (selected studies) 2 215 -.490 .122 -.730        -.250 .000 
 
 


























Antoni (2001) CES-D 1 100 -.072 .199 -.462        .317 .716 
Arving (2007)a HADS 1 179 -.366 .131 -.623       -.109 .005 
Kissane (2003) HADS 1 303 -.045 .115 -.270        .179 .693 
Marchioro (1996) BDI 1 36 -.467 .331 -1.115      .181 .158 
Overall  
(selected studies) 
4 618 -.193 .101 -.391        .004 .055 
Hedge’s g and 95% CI 
Hedge’s g and 95% CI 








Figure 7. Depression by CBT-BI for selected studies from pre-treatment to 12-month follow-up (longer-term effect). A negative effect indicates that 



































Antoni (2001) CES-D 1 100 -.462 .201 -.857      -.067 .022 
Kissane (2003) HADS 1 303 -.127 .115 -.352       .098 .268 
Overall  
(selected studies) 
4 618 -.253 .162 -.571       .064 .118 
Hedge’s g and 95% CI 
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3.3.2.3 Pre-treatment to 12-month follow-up. 
Two studies examined the longer-term effect of CBT-BI on depression at 12-month 
follow-up (see Figure 7). The overall effect size was small and non-significant (nstudies = 2, 
Hedge’s g = -.253, 95% CIs [-.571, .064]; Nfs < Nstudies; p = .118). Specifically, Antoni et al. 
(2001) reported a medium and significant effect (Hedges g = -.462, p = .022), however, 
Kissane et al. (2003) reported a small and non-significant effect (Hedges g = -.127, p = .268). 
The strength and lack of significance of the overall effect could be attributed to the latter 
study being assigned the bulk of the weighting (62.25%). A moderate level of between-
studies heterogeneity (I2 = 52%) was also noted, potentially reflecting Antoni et al's (2001) 
focus on CBSM, with participants receiving a lower number of intervention sessions (10 
weekly sessions), as opposed to Kissane et al's (2003) focus on CEGT and double the number 
of intervention sessions. The 𝑁𝑓𝑠 was less than the number of studies included in the analysis, 
suggesting that these findings may be influenced by publication bias. 
3.4 Quality Findings 
3.4.1 Risk of bias assessment. 
All studies were assessed on their risk of bias, with results highlighting that all 
incorporated random sampling methods (e.g., computer generated sampling, random blocks 
or tables of numbers) for recruitment, making them all low-risk for selection bias (see Table 
4). Although, selection bias was unclear due to insufficient data reported on blinding of 
participants and outcomes in the studies. Five out of the six (83%) studies (Arving et al., 
2007; Desautels et al., 2018; Kissane et al., 2003; Marchioro et al., 1996; Mohabbat-Bahar et 
al., 2015) reported low rates of incomplete intervention outcome data for CBT-BI and half of 
the studies (Kissane et al., 2003; Marchioro et al., 1996; Mohabbat-Bahar et al., 2015) 
reported low rates of incomplete control outcome data, with reasons. Therefore, important 
bias would not be expected and overall, the majority of the studies were classified as low risk 
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Note: Adapted from “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” by J. P. 
Higgins et al., (2011). 
* Studies with no reports of missing data for both intervention and control groups were considered to be low 
risk on both. 
a Studies with three intervention groups (2 intervention/treatment groups and 1 control group). b Studies for 
which only 1 of the 2 intervention groups was relevant and the risk of bias for which is reported on the table. 
 
3.4.2 Quality assessment of the included studies. 
Study quality was examined using the QI (see Appendix D). Results revealed study 
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Arving et al. (2007) a 
    
 
  
Desautels et al. (2018) 
       
Kissane et al. (2003) 
       
Machioro et al. (1996)*a, b 
       
Mohabbat-Bahar et al. (2015)*a, b 
       
 
Low risk of bias 
 
High risk of bias 
 
Unclear risk of bias 
Key 
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quality study designs (see Table 5).  
The level of reporting in the studies was sound, with only one study’s (Arving et al., 
2007)  losses to follow-up being unable to be determined, and just one study (Mohabbat-
Bahar et al., 2015) not reporting exact p-values. Additionally, Item 8 on the QI was unclear 
as it was not reported.  
Conversely, external validity or generalisability of the data was somewhat 
compromised. While most studies at least partially reported data on source population and 
characteristics, only one study double-blinded personnel and participants (Desautels et al., 
2018). Furthermore, intervention compliance was only reported by one third of the studies 
(Desautels et al., 2018; Kissane et al., 2003). Nonetheless, all studies presented good external 
validity on the latter QI Items (16-20), which included using valid and accurate measures of 
depression (e.g., HADS, BDI-II), and appropriate statistical testing. Lastly, inclusion and 
exclusion criteria were routinely reported, with potential participants with pre-existing mental 
conditions (e.g., anxiety) excluded to enhance generalisability of the findings. Positively, 
external validity was heightened due to participants hailing from various countries.  
Thirdly, internal validity was moderately well-reported across studies. Random 
allocation of participants to group assignment was done in all studies using comparable 
groups, while recruitment time was reported at least partially by all studies, except one 
(Antoni et al., 2001). As is typical in psychotherapy research (Schnurr, 2007) participants and 
assessors were generally informed of group assignment, with only Desautels et al. (2018) 
incorporating blinded intervention group allocation. Importantly, all studies reported the 
number of participants lost to follow up. Intent-to-treat analyses, implying the assessment of 
all participants who were initially randomised including dropouts were utilised by half of the 
studies (Antoni et al., 2001; Arving et al., 2007; Desautels et al., 2018).  
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Lastly, 50% of the studies (Antoni et al., 2001; Arving et al., 2007; Kissane et al., 
2003) obtained good power by meeting the minimum sample size to achieve a large and 
statistically significant effect met the minimum sample size to achieve a large and statistically 
significant effect (i.e., Nparticipants = 26, power at .80, α = .05; Cohen, 1992).  





 Evaluation of Included Studies (Nstudies = 6) Using the Quality Index  
 Note.   present (score of 1, or 2 for item 5);   present, with some limitations (score of 0);  not present or unable to determine (score of 0). Item 27: Necessary N for power of 















































































































































































































































































































































































































































































Antoni et al. (2001)                            20/27 
Arving et al. (2007)                            20/27 
Desautels et al. (2018)                            24/27 
Kissane et al. (2003)                            21/27 
Machioro et al. (1996)                            17/27 
Mohabbat-Bahar et al. (2015)                            15/27 
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3.4.3 Quality assessment of intervention descriptions. 
Intervention descriptions were assessed using TIDieR Checklist (see Appendix E). 
Results demonstrate that the number of fulfilled criteria ranged from five to 10 (see Table 6). 
Four studies (Antoni et al., 2001; Arving et al., 2007; Desautels et al., 2018; Kissane et al., 
2003) described interventions in sufficient detail to allow replication, reporting on at least 
eight of the 12 items, with no studies modifying interventions, rendering Item 10 not 
applicable. In the majority of the studies, all participants within treatment and control groups 
were given the same intervention, except one study (Arving et al., 2007) that tailored its 
intervention to the participants. Therefore, Items nine and 10 were not applicable to most 
studies. Information on intervention characteristics (i.e., brief name, rationale, procedure, 
modes of delivery, when and how much) were consistently reported by all studies at least 
partially. Half of the studies (Antoni et al., 2001; Arving et al., 2007; Desautels et al., 2018) 
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Note.   present;   present, with some limitations;  not present or unable to determine 
 
3.4.4 Quality assessment of researcher allegiance. 
RA was assessed using the RA checklist (see Appendix F). Results exhibit that all 
studies were allegiant RCTs and evidence of author’s allegiance was provided in the 
publications (see Table 7). The majority of the studies (Antoni et al., 2001; Arving et al., 
2007; Desautels et al., 2018; Kissane et al., 2003) were moderately weak allegiant studies 
(allegiance = code 3), indicating that authors advocated for treatment and trained the 
therapist. Two studies (Marchioro et al., 1996; Mohabbat-Bahar et al., 2015) were weak 
allegiant studies (allegiance = code 1) as they explained the intervention in the introduction 

















































































































































































































































Antoni et al. (2001)             
Arving et al. (2007)             
Desautels et al. (2018)             
Kissane et al. (2003)             
Machioro et al. (1996)             
Mohabbat-Bahar et al. (2015) 
            
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Antoni et al. (2001)       
Arving et al. (2007)       
Desautels et al. (2018)       
Kissane et al. (2003)       
Machioro et al. (1996)       
Mohabbat-Bahar et al. (2015)       
Note.   present;  not present or unable to determine
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Chapter 4: Discussion 
4.1 Key Findings 
This meta-analysis examined the effectiveness of CBT-BI on depression in women 
with non-metastatic breast cancer. Analyses of short- and longer-term effects, and study 
quality were assessed for six studies involving 710 participants. The results of this study 
highlighted that CBT-BI was significant in reducing depression in some contexts: overall 
short-term, short-term individual CBT-BI, and at three-month follow-up. However, these 
results were not maintained at six- and 12-month follow-up. Lastly, the included studies were 
of moderate quality. In combination, these findings suggest that CBT-BI are efficacious in 
reducing depression in women with non-metastatic breast cancer, albeit differences in 
efficacy are noted depending on time since intervention. 
4.1.1 Short-term findings. 
4.1.1.1 Overall short-term findings. 
Results of this review exhibit that CBT-BI is highly effective in the short-term, 
concurring with existing evidence (Qiu et al., 2013; Tatrow & Montgomery, 2006). Of these, 
Tatrow & Montgomery (2006) found a smaller effect size (d = 0.31) compared to the current 
study, which, although speculative, may be credited to intervention variations in both studies. 
Nonetheless, previous research has concluded that short-term psychological interventions, 
involving psychoeducation and directed at specific behaviour change and cognitive 
restructuring, confer positive effects on emotional adjustment in breast cancer patients 
(Barsevick et al., 2002; Cohen & Fried, 2007; Meyer & Mark, 1995; Osborn, Demoncada, & 
Feuerstein, 2006).  
Notably, the current findings were characterised by substantial sample heterogeneity, 
although common in RCTs among such populations and is usually driven by variability in 
participants and interventions between studies Corbett, Devane, Walsh, Groarke, & McGuire, 
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2015; Haidich, 2010), no firm conclusions can be drawn. Considering the small sample of 
studies included, over- or under-estimation of heterogeneity is common, however, this was 
accounted for by utlising a random-effects meta-analysis model (DerSimonian & Laird, 
1986; Von Hippel, 2015). Furthermore, heterogeneous samples strengthen applicability of 
CBT-BI across a range of ages and diverse cancer types and stages (Carlson & Garland, 
2005). 
4.1.1.2 Individual versus group CBT-BI. 
Individual CBT-BI was significantly associated with reduced depression compared to 
controls. This finding coincides with previous research showing significantly large effects for 
individual CBT-BI compared to patients in control groups (Tatrow & Montgomery, 2006; 
Xiao et al., 2017). Secondly, the current finding of no significant difference in depression 
levels between group CBT-BI and control groups, juxtapose previous findings suggesting 
benefits of group processes (e.g., reassurance, instilling hope) (Cohen & Fried, 2007; Qiu et 
al., 2013; Simpson et al., 2001; Spiegel, Bloom, & Yalom, 1981). This discrepancy in results 
could be attributed to a range of factors including presence of outliers, group characteristics, 
therapist approach, or differing intervention designs (Cohen & Fried, 2007; Tatrow & 
Montgomery, 2006). Additionally, the present study demonstrated a lack of evidence for the 
superiority of one method of CBT-BI delivery over the other. Again, these findings juxtapose 
previous literature which often states that either individual CBT-BI is more efficacious than 
group CBT-BI (Greer et al., 1992; Tatrow & Montgomery, 2006) due to tailored treatment 
and rapport building, or that the latter is more effective than the former, due to group 
processes (Spiegel et al., 1981). However, in comparison with the current study, Spiegel and 
colleagues’ (1981) research was specific to metastatic rather than non-metastatic breast 
cancer, which could contribute to these discrepant findings. Larger scale studies comparing 
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individual and group therapy formats in non-metastatic breast cancer populations are required 
to definitively determine if one is more effective than the other.  
4.1.2 Longer-term findings. 
Researchers often wonder if CBT-BI sustain their effects over time. The current 
research results display that for three-month follow-up, there was a moderate and significant 
effect of CBT-BI on depression, compared to controls. Previous literature assessing CBT-
BI’s longer-term effects in breast cancer populations is scarce, however, the current results 
are consistent with one study (Greer et al., 1992) which suggested that CBT-BI reduced 
depression at four-month follow-up.  
The persistence of CBT-BI effects at six-month follow-up was also analysed. Overall, 
results revealed that while initially, depression dropped significantly following CBT-BI, 
changes were not maintained at six-month follow-up. These results correspond with 
conclusions from previous literature (Hollon, Thase, & Markowitz, 2002), suggesting that 
effects of CBT-BI substantially weaken, if not disappear entirely, once the intervention 
discontinues. While some have suggested that CBT-BI is associated with general long-term 
effectiveness and relapse prevention (Simons, Levine, Lustman, & Murphy, 1984), others 
have stated that CBT-BI is not effectual at all in the long-term (Haller et al., 2017). These 
divergent results could be linked to intervention differences, duration of treatment in the 
studies (10-28 weeks), differences in therapists’ skills, varying outcomes measures and 
follow-up assessment time-points, as well as depression severity (Butler et al., 2006; Cohen 
& Fried, 2007; Dobson, 1989). Additionally, previous analyses of CBT-BI and depression 
have revealed that personal factors (e.g., age, number of previous depressive episodes, 
baseline depression levels, remaining depressive symptoms at treatment completion) and 
social contexts may affect responses to CBT-BI, and thus, may account for variance present 
in the current findings (Kovacs, Rush, Beck, & Hollon, 1981; Mitchell et al., 2011; Simons, 
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Murphy, Levine, & Wetzel, 1986; Yang et al., 2014). However, these arguments are 
tautological and require further empirical testing via longitudinal studies (Kovacs et al., 
1981).  
Similar to the six-month follow-up results, CBT-BI gains were not maintained at 12-
month follow-up, in contrast to previous literature (Stagl et al., 2015). Kovacs et al. (1981) 
suggest that such CBT-BI relapse, as observed in this meta-analysis, could be attributed to 
insufficient intervention potency. The studies included in this sub-analysis (Antoni et al., 
2001; Kissane et al., 2003) had a stronger focus on behavioural components (e.g., stress 
monitoring skills, emotional support) rather than cognitive restructuring, which may have 
resulted in similarities in depression between intervention and control groups at 12-month 
follow-up. Similar to three-month follow-up, there was a limited number of studies in this 
sub-group analysis, underlining the need for additional primary research exploring CBT-BI’s 
longer-term effects for depression in women with non-metastatic breast cancer.  
4.1.3 Quality findings. 
The current results should be interpreted in the context of study quality, which was 
assessed using risk of bias, study quality, intervention descriptions and RA. Firstly, this 
study’s risk of bias assessments demonstrated low attrition bias, no selection and reporting 
biases, indicating that included studies had sufficient data despite dropouts, random sequence 
of allocation of intervention to participants, and no direct evidence for selective outcome 
reporting, which were strengths of the studies. These findings juxtapose Haller et al’s (2017) 
findings of high attrition bias and Cramer et al’s (2012) high reporting bias. Differences in 
included study designs and interventions may have caused these discrepant findings.  
Second, study quality found that studies reported adequately on sample data, 
intervention and outcomes. Internal and external validity were moderately well-reported, with 
all studies using standardised outcome measures and participant randomisation, although 
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blinding methods were inconsistently described. However, double-blinding is not always 
practical or possible in psychotherapy research, but, quality can still be shown as long as 
alternative research designs are well-justified, with confounders well- understood, 
documented and measured (Bonell et al., 2009; Dragioti et al., 2015), points which were 
consistently covered by all included studies. Studies used intent-to-treat analyses, which is 
often suggested to decrease Type I error (Lachin, 2000), and thus, recommended for 
psychotherapy research (Schnurr, 2007). Overall, these quality results contradicted the 
majority of low quality studies found by two previous meta-analyses (David, Cotet, Matu, 
Mogoase, & Stefan, 2018; Xiao et al., 2017; Zhang et al., 2016), where the eight criteria by 
Cuijpers et al. (2010) and the Jadad Scale (Jadad et al., 1996) were used to assess quality, 
respectively. Due to the lack of prior evidence on quality assessments using the QI, direct 
quality comparisons cannot be made. 
Additionally, studies’ intervention descriptions were assessed using the TIDieR 
Checklist (Hoffmann et al., 2014). The findings established that the included studies 
consistently reported on treatment descriptions, however, intervention locations were seldom 
reported. Finally, findings from the RA checklist (Wampold et al., 2011) highlighted that 
overall, studies were weakly or moderately allegiant, indicating lack of reporting bias. 
However, for both TIDieR intervention descriptions and RA, definitive conclusions cannot be 
drawn due to insufficient data provided in some studies, which is warranted, given the 
evolving nature of reporting criteria and expectations that have occurred over time. Most of 
the included studies were published prior to such expectations. Given that RA is a recent 
development, when paired with a lack of strict reporting policy, it is unlikely to be reported in 
meta-analyses and RCTs (Dragioti et al., 2015). However, in current times, 
psychotherapeutic research ought to report on these essential aspects.  
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4.2 Clinical Implications and Future Research 
Findings from this comprehensive analysis of CBT-BI have implications for 
management of depression in women with non-metastatic breast cancer and highlight 
promising avenues for clinical practice and research. First and foremost, these results 
enhance understandings of the efficacy of CBT-BI in reducing depression in women with 
non-metastatic breast cancer, and are feasible to be delivered as an evidence-based therapy 
for depression in oncology settings (Sturmey, 2009). Furthermore, the quality assessments 
conducted in the current study allow clinicians to assess research evidence, better able to 
confidently plan their evidence-based approach by considering factors such as length of time 
delivered and setting of delivery. 
Many remaining moderator analyses (e.g., comparisons of specific CBT-BI 
techniques; moderators of age, social context, quality of life, biological therapy used) 
(Dobson, 1989; Reich et al., 2008; Trudel-Fitzgerald, Savard, & Ivers, 2013) beyond the 
scope of the present research, could be undertaken. Additionally, evidence suggests that 
certain stages in the disease trajectory result in differing levels of patient vulnerability, who 
may need more or less psychological support (Trudel-Fitzgerald et al., 2013), are avenues for 
future research to analyse treatment engagement and compliance. As the literature grows, it is 
hoped that such areas will be pursued to confidently establish moderating effects.  
Finally, while this meta-analysis analysed longer-term effects of CBT-BI on 
depression among women with  non-metastatic breast cancer, there is a need for primary 
research, particularly RCTs, to examine these effects. Fuelling a greater evidence base will 
allow for the establishment of a highly effective form of therapy before researchers can begin 
to address the question of possible beneficiaries of CBT-BI (Dobson, 1989).  
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4.3 Study Limitations and Strengths 
Findings must be considered in light of the study limitations. Firstly, due to the small 
number of studies included, analyses should be viewed with caution, particularly the 
individual versus group CBT-BI, and three- and six-month follow-up sub-analyses, which 
were underpowered due to not meeting suggested minimal requirements of having four 
studies (Borenstein et al., 2009). Nonetheless, low-powered analyses can still provide useful 
insights by revealing deficiencies in the CBT-BI, depression and breast cancer literature that 
deserve further exploration (Greco, Zangrillo, Biondi-Zoccai, & Landoni, 2013). Overall, the 
small number of studies is attributable to this study’s rigorous inclusion criteria. While only 
six studies were included, there is no universally accepted minimum number of studies, but 
Fu et al. (2011) states that a minimum of 6 studies has been accepted by Cochrane as 
sufficient for meta-analyses, suggesting it was appropriate to proceed with the current meta-
analysis. Nonetheless, the present study should be viewed as both a commentary on the fact 
that this area of study is under-researched, as well as a catalyst for future, well-designed 
investigations. Also, despite the small number of included studies, this review contained data 
from variety of countries, therefore, making it cross-culturally applicable and extending the 
external validity of the study.  
Secondly, the included studies reported ambiguous or incomplete data on aspects of 
the intervention (e.g., length of intervention, professional delivering intervention). However, 
Dobson (1989) found that CBT-BI gains were not significantly related to length of 
intervention. Also, intervention characteristics varied across the studies, suggesting possible 
heterogeneity. Although psychotherapy research contains some inherent heterogeneity, the 
included studies used treatment manuals with prescribed goals and techniques to minimise 
variability between therapists.  
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It could also be suggested that broader inclusion criteria may have expanded the 
number of eligible studies. However, strict criteria provides the current study with an 
advantage from previous meta-analyses (i.e., Cramer et al., 2012; Haller et al., 2017; Xiao et 
al., 2017) due to its focus on breast cancer patients only, thereby reducing heterogeneity 
associated with including a broad range of cancers with variable participant diagnoses 
(Tatrow & Montgomery, 2006). Additionally, the rigorous inclusion criteria also allowed 
outcomes to be applicable to specific breast cancer patients, which, as lack of evidence 
suggests, is an underresearched area (Greco et al., 2013). Moreover, multiple search terms 
and synonyms, and different combinations of these, improved effectiveness and sensitivity of 
the literature search by preventing potentially relevant articles from being missed (Bown & 
Sutton, 2010; Singh, 2017). To further address the problem of eligible studies being missed in 
database searches, Nfs was calculated, albeit, this statistic does not fully alleviate the ‘file 
drawer problem’ (Lipsey & Wilson, 2001). 
Although limitations are acknowledged, this meta-analysis also encompasses many 
strengths. Presently, it is the first formal meta-analysis that comprehensively investigated 
CBT-BI in non-metastatic breast cancer populations, and doing so by using RCTs only. 
Additionally, the extensive quality assessments conducted in this research, including TIDieR 
and RA, added to this study’s strengths. This, paired with the stringent inclusion criteria and 
extensive database searches, highlighted the sound design of this meta-analysis. 
4.4 Conclusions 
 This systematic review and meta-analysis, in conjunction with other published CBT-
BI literature for depression in breast cancer populations, revealed that CBT-BI present 
significant promise in reducing depression in the short-term, especially when delivered in an 
individualised setting. The findings have significant implications for the development of 
psychological intervention strategies and future research. Notably, results of this meta-
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analysis provide support for further application of CBT-BI, however, several aspects of CBT-
BI are still underresearched or misunderstood. Thus, further large-scale primary, and 
longitudinal research examining moderating variables in the treatment process that influence 
CBT-BI gains in breast cancer populations, is warranted. Consequently, this data can be used 
to guide recommendations on EBP standards and promote the creation of optimal and tailored 
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malignan*.tw OR breast 
carcinoma*.tw OR ductal 
carcinoma*.tw OR lobular 
carcinoma*.tw OR cancer* of 
the breast*.tw OR carcinoma 
of the breast*.tw OR 
neoplasm of the breast*.tw 
OR non-metastatic breast 
cancer*.tw OR non-metastatic 










OR distress*.tw OR 
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Web of Science 
Breast Cancer Depression CBT Study Type 
TS=(“breast neoplas*” OR 
“breast cancer*” OR “breast 
tumour*” OR “breast tumor*” 
OR “breast malignan*” OR 
“breast carcinoma*” OR 
“ductal carcinoma*” OR 
“lobular carcinoma*” OR 
“cancer of the breast*” OR 
“carcinoma of the breast*” OR 
“neoplasm of the breast*” OR 
“non-metastatic breast 
cancer*” OR “non-metastatic 
breast neoplasm*” OR “non-


















therap*" OR “cognitive 
behav* therap*” OR 
“cognitive behav*” OR 
“mindful* based 
cognitive therap*” OR 
“cognitive behav* 
stress management” OR 
TI CBSM OR TI CBT 























Breast Cancer Depression CBT Study Type 
MH “breast neoplasm*” OR 
MH “breast carcinoma*” OR 
TI “breast neoplas*” OR AB 
“breast neoplas*” OR TI 
“breast cancer*” OR AB 
“breast cancer*” TI “breast 
tumo#r*” OR AB “breast 
tumo#r*” OR TI “breast 
malignan*” OR AB “breast 
malignan*”OR TI “breast 
carcinoma*” OR AB “breast 
carcinoma*” OR TI “ductal 
carcinoma*” OR AB “ductal 
carcinoma*” OR TI “lobular 
carcinoma*” OR AB “lobular 
carcinoma*” OR TI “cancer 
of the breast*” OR AB 
“cancer of the breast*” OR TI 
“carcinoma of the breast*” 
OR AB “carcinoma of the 
breast*” OR TI “neoplasm of 
the breast*” OR AB 
“neoplasm of the breast*” OR 
TI “non-metastatic breast 
cancer” OR AB “non-
MH depression 
OR TI depression 
OR AB depression 
OR TI “depressive 
disorder” OR AB 
“depressive 
disorder” OR TI 
depressive OR AB 
depressive OR TI 
depressed OR AB 
depressed OR TI 
distress* OR AB 
distress* OR TI 
“major depressive 
disorder*” OR AB 
“major depressive 
disorder*” OR TI 
“major depressive 
episode*” OR AB 
“major depressive 
episode*” OR TI 
“depressive 
disorder*” OR AB 
“depressive 
disorder*” OR TI 
MH “cognitive 
therapy" OR TI 
“cognitive therap*" 
OR AB “cognitive 
therap*” OR TI 
“cognitive behav* 
therap*” OR AB 
“cognitive behav* 
therap*” OR  TI 
“cognitive behav*” 
OR AB “cognitive 
behav*” OR TI 
“mindful* based 
cognitive therap*” 
OR AB “mindful* 
based cognitive 
therap*” OR TI 
“cognitive behav* 
stress management” 
OR AB “cognitive 
behav* stress 
management” OR TI 
CBSM OR AB 
CBSM OR TI CBT 
OR AB CBT OR TI 
MH “random 
assignment” OR MH 
“random* control 
trial*” OR MH 
“clinical trial*” OR TI 
“random* 
assignment” OR AB 
“random* 
assignment” OR TI 
“clinical trial*” OR 
AB “clinical trial*” 
OR TI “random* 
allocation” OR AB 
“random* allocation” 
OR TI “random* 
control trial*” OR AB 
“random* control 
trial*”OR TI random* 
OR AB random* OR 
TI “random* control 
trial*” OR AB 
“random* control 
trial*” OR TI RCT* 
OR AB RCT*OR TI 
“controlled clinical 
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metastatic breast cancer*” 
OR TI “non-metastatic breast 
neoplasm*” OR AB “non-
metastatic breast neoplasm*” 
OR TI “non-metastatic breast 
carcinoma*” OR AB “non-
metastatic breast carcinoma*” 
“depressive 












trial*” OR AB 
“controlled clinical 
trial*” OR TI 
“random* clinical 










Breast Cancer Depression CBT Study Type 
'breast cancer'/exp OR 
'breast carcinoma'/exp OR 
'breast carcinoma*’:ti,ab OR 
'breast neoplasm*':ti,ab OR 
'breast cancer*':ti,ab OR 
'breast tumo$r*':ti,ab OR 
'breast malignancy':ti,ab OR 
'breast carcinoma*':ti,ab OR 
'ductal carcinoma*':ti,ab OR 
'lobular carcinoma*':ti,ab 




















OR ‘major depress* 






































Breast Cancer Depression CBT Study Type 
TITLE-ABS-KEY ("breast 
neoplasm*" OR "breast 
cancer*" OR "breast tumour*" 
OR "breast malignan*" OR 
"breast carcinoma*" OR "ductal 
carcinoma*" OR "lobular 
carcinoma*" OR "cancer* of 
the breast" OR “carcinoma of 
the breast*” OR “neoplasm of 
the breast*” OR “non-
metastatic breast cancer*” OR 
“non-metastatic breast 
neoplasm*” OR “non-





“depress* mood” OR 
“feelings of distress” OR 
“emotional distress” OR 
“major depress*” OR 
“depress* episode” OR 
“major depress* 
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Person extracting data:  
 
Date of date extraction: 
 





Other publications from same study (additional reports of the same study should be grouped under the 
same study identifier see “Organising studies and references”, p 35 RevMan User Guide): 
 
 
Type of study design (e.g., parallel; cluster; cross-over trial) 
Study Country: 
Total sample size:   
 
Experimental intervention:  
 
Total number randomised: n=  
 
Control/Comparison intervention:  
Total number randomised: n=  
 
Specify Treatment Group: 








































Setting of CBT treatment: 
Individual: 
Group: 
Specify Control Group – if 
different from treatment 
population 
 









[✓] From subject 
[ ] Medical records 




[  ] No 
 
Eligibility Criteria Specified 
[✓] Yes           [  ] No 
[  ] Partially 
 
General Population 
[ ] Yes           [✓] No 
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Nature of breast cancer (% or 
n) 
Stage 0: 
Stage 1:  

















Missing Data explained 
[✓] Yes           [  ] No 
[  ] Partially 
 
Sample recruitment 
[✓] Not specified 
[  ] Hospital Inpatient 
[  ] Database 
[  ] Rehab Clinic 




Effect size data: 
Outcome measure:  
Method of administration: self-report [  ]    clinical interview [  ]     DASS [  ]      BDI-II [  ]      HADS [  
]         other [ ] 
Cut-off score (if applicable):  
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Risk of Bias Assessment 
 
Domain Risk of bias Support for judgement 
(include direct quotes where available 
with explanatory comments) 
Location in text or 
source (pg & 





   




   






   
Outcome group: All/      
      





   
Outcome group:       
      





   
Outcome group: All/      
      





   
Outcome group:       
      




   
Outcome group: All/      
      





   
Outcome group:       






   
            
Other bias                
Notes:         
 





Downs and Black QI 
 
 
Eligible Studies (n = ) 
Lead Author of Study:  Notes/Justification 
Reporting 0 (= No) 1 (= Yes) 0 (= Unable to 
determine) 
 
1. Is the hypothesis/aim/objective of the study clearly described?      
2. Are the main outcomes to be measured clearly described in the 
Introduction or Methods section? If the main outcomes are first mentioned 
in the Results section, the question should be answered no.  
    
3. Are the characteristics of the patients included in the study clearly 
described ? In cohort studies and trials, inclusion and/or exclusion criteria 
should be given. In case‐control studies, a case‐definition and the source for 
controls  
    
4. Are the interventions of interest clearly described? Treatments and 
placebo (where relevant) that are to be compared should be clearly 
described.  
    
5. Are the distributions of principal confounders in each group of subjects 
to be compared clearly described? A list of principal confounders is 
provided.  
    
6. Are the main findings of the study clearly described? Simple outcome data 
(including denominators and numerators) should be reported for all major 
findings so that the reader can check the major analyses and conclusions. 
    




(This question does not cover statistical tests which are considered below). 
7. Does the study provide estimates of the random variability in the data for 
the main outcomes? 
In non normally distributed data the inter‐quartile range of results should be 
reported. In normally distributed data the standard error, standard deviation 
or confidence intervals should be reported. If the distribution of the data is 
not described, it must be assumed that the estimates used were appropriate 
and the question should be answered yes.  
    
8. Have all important adverse events that may be a consequence of the 
intervention been reported? This should be answered yes if the study 
demonstrates that there was a comprehensive attempt to measure adverse 
events. (A list of possible adverse events is provided).  
    
9. Have the characteristics of patients lost to follow‐up been described? This 
should be answered yes where there were no losses to follow‐up or where 
losses to follow‐up were so small that findings would be unaffected by their 
inclusion. This should be answered no where a study does not report the 
number of patients lost to follow‐up.  
    
10. Have actual probability values been reported ( e.g. 0.035 rather than 
<0.05) for the main outcomes except where the probability value is less than 
0.001?  
    
External Validity  
All the following criteria attempt to address the representativeness of the 
findings of the study and whether they may be generalised to the population 
    




from which the study subjects were derived.  
11. Were the subjects asked to participate in the study representative of the 
entire population from which they were recruited?  
The study must identify the source population for patients and describe how 
the patients were selected. Patients would be representative if they 
comprised the entire source population, an unselected sample of 
consecutive patients, or a random sample. Random sampling is only feasible 
where a list of all members of the relevant population exists. Where a study 
does not report the proportion of the source population from which the 
patients are derived, the question should be answered as unable to 
determine.  
    
12. Were those subjects who were prepared to participate representative of 
the entire population from which they were recruited? The proportion of 
those asked who agreed should be stated. Validation that the sample was 
representative would include demonstrating that the distribution of the main 
confounding factors was the same in the study sample and the source 
population.  
    
13. Were the staff, places, and facilities where the patients were treated, 
representative of the treatment the majority of patients receive? For the 
question to be answered yes the study should demonstrate that the 
intervention was representative of that in use in the source population. The 
question should be answered no if, for example, the intervention was 
undertaken in a specialist centre unrepresentative of the hospitals most of 
the source population would attend.  
    
Internal validity – bias     




14. Was an attempt made to blind study subjects to the intervention they 
have received? For studies where the patients would have no way of 
knowing which intervention they received, this should be answered yes.  
    
15. Was an attempt made to blind those measuring the main outcomes of 
the intervention?  
    
16. If any of the results of the study were based on “data dredging”, was this 
made clear? Any analyses that had not been planned at the outset of the 
study should be clearly indicated. If no retrospective unplanned subgroup 
analyses were reported, then answer yes.  
    
17. In trials and cohort studies, do the analyses adjust for different lengths of 
follow‐up of patients, or in case‐control studies, is the time period 
between the intervention and outcome the same for cases and 
controls? Where follow‐up was the same for all study patients the answer 
should yes. If different lengths of follow‐up were adjusted for by, for 
example, survival analysis the answer should be yes. Studies where 
differences in follow‐up are ignored should be answered no.  
    
18. Were the statistical tests used to assess the main outcomes appropriate? 
The statistical techniques used must be appropriate to the data. For example 
nonparametric methods should be used for small sample sizes. Where little 
statistical analysis has been undertaken but where there is no evidence of 
bias, the question should be answered yes. If the distribution of the data 
(normal or not) is not described it must be assumed that the estimates used 
were appropriate and the question should be answered yes.  
    
19. Was compliance with the intervention/s reliable? Where there was non 
compliance with the allocated treatment or where there was contamination 
of one group, the question should be answered no. For studies where the 
    




effect of any misclassification was likely to bias any association to the null, 
the question should be answered yes.  
20. Were the main outcome measures used accurate (valid and reliable)? For 
studies where the outcome measures are clearly described, the question 
should be answered yes. For studies which refer to other work or that 
demonstrates the outcome measures are accurate, the question should be 
answered as yes.  
    
Internal validity ‐ confounding (selection bias)      
21. Were the patients in different intervention groups (trials and 
cohort studies) or were the cases and controls (case‐control studies) 
recruited from the same population? For example, patients for all 
comparison groups should be selected from the same hospital. The question 
should be answered unable to determine for cohort and casecontrol studies 
where there is no information concerning the source of patients included in 
the study.  
    
22. Were study subjects in different intervention groups (trials and 
cohort studies) or were the cases and controls (case‐control studies) 
recruited over the same period of time? For a study which does not specify 
the time period over which patients were recruited, the question should be 
answered as unable to determine.  
    
23. Were study subjects randomised to intervention groups? Studies which 
state that subjects were randomized should be answered yes except where 
method of randomisation would not ensure random allocation. For example 
alternate allocation would score no because it is predictable.  
    
24. Was the randomised intervention assignment concealed from     




both patients and health care staff until recruitment was complete 
and irrevocable? All non‐randomised studies should be answered no. If 
assignment was concealed from patients but not from staff, it should be 
answered no.  
25. Was there adequate adjustment for confounding in the analyses from 
which the main findings were drawn? This question should be answered no 
for trials if: the main conclusions of the study were based on analyses of 
treatment rather than intention to treat; the distribution of known 
confounders in the different treatment groups was not described; or the 
distribution of known confounders differed between the treatment groups 
but was not taken into account in the analyses. In nonrandomized studies if 
the effect of the main confounders was not investigated or confounding was 
demonstrated but no adjustment was made in the final analyses the 
question should be answered as no.  
    
26. Were losses of patients to follow‐up taken into account? If the numbers 
of patients lost to follow‐up are not reported, the question should be 
answered as unable to determine. If the proportion lost to follow‐ up was 
too small to affect the main findings, the question should be answered yes.  
    
Power      
27. Did the study have sufficient power to detect a clinically important effect 
where the probability value for a difference being due to chance is less than 
5%? Sample sizes have been calculated to detect a difference of x% and y%.  
    
Total score:   /27     
Note.   present (score of 1, or 2 for item 5);   present, with some limitations (score of 0);  not present or unable to determine (score of 0). 











Lead author of study:  Where located ** 
 Primary paper 
(page or appendix 
number) 














3. Materials: Describe any physical or informational materials used in the intervention, including those 
provided to participants or used in intervention delivery or in training of intervention providers. 























5. For each category of intervention provider (e.g. psychologist, nursing assistant), describe their 
expertise, background and any specific training given. 
 
_________ _____________ 
6. Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or 





7. Describe the type(s) of location(s) where the intervention occurred, including any necessary 
infrastructure or relevant features. 
_________ _____________ 
  
WHEN and HOW MUCH 
  
8. Describe the number of times the intervention was delivered and over what period of time including 





9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, 
and how. 
_________ _____________ 








10.ǂ If the intervention was modified during the course of the study, describe the changes (what, why, 





11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any 





Actual: If intervention adherence or fidelity was assessed, describe the extent to which the 
intervention was delivered as planned. 
 
_________ _____________ 
Note.  present (score of 1);   present, with some limitations (score of 0);  not present or unable to determine (score of 0). 
Authors - use N/A if an item is not applicable for the intervention being described. Reviewers – use ‘?’ if information about the element is not reported/not 
sufficiently reported.         




Researcher Allegiance Assessment Sheet  
 
Note.  present;   present, with some limitations;  not present or unable to determine. 
Author - use N/A if an item is not applicable for the intervention being described.  
 















Location in text 





0. No apparent advocacy 
of one treatment over 
another 
   
   
1. Treatment explanation 
occurred in 
introduction/methods 
   
   
2. Authors advocated for 
treatment but did not 
supervise/train therapist 
   
   
3. Authors advocated for 
treatment and they 
supervised/trained 
therapist 
   
   
4. Authors created 
intervention but did not 
supervise/train therapist 
   
   




   
   
Notes: 
